相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Correlations between serum cetuximab and EGFR-related markers, and skin disorders in head and neck cancer patients
Kaito Shibata et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2021)
Precision Medicine Approaches to Overcome Resistance to Therapy in Head and Neck Cancers
Sandra Ortiz-Cuaran et al.
FRONTIERS IN ONCOLOGY (2021)
Immuno-radiotherapy with cetuximab and avelumab for advanced stage head and neck squamous cell carcinoma: Results from a phase-I trial
Joris B. W. Elbers et al.
RADIOTHERAPY AND ONCOLOGY (2020)
Interleukin 6 is increased in preclinical HNSCC models of acquired cetuximab resistance, but is not required for maintenance of resistance
Rachel A. O'Keefe et al.
PLOS ONE (2020)
Biological Determinants of Chemo-Radiotherapy Response in HPV-Negative Head and Neck Cancer: A Multicentric External Validation
Martijn van der Heijden et al.
FRONTIERS IN ONCOLOGY (2020)
Pathway-Specific Genome Editing of PI3K/mTOR Tumor Suppressor Genes Reveals that PTEN Loss Contributes to Cetuximab Resistance in Head and Neck Cancer
Hiroki Izumi et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J-P Machiels et al.
ANNALS OF ONCOLOGY (2020)
Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma
Olivia Leblanc et al.
CANCER BIOLOGY & MEDICINE (2020)
Immunogenomic correlates of response to cetuximab monotherapy in head and neck squamous cell carcinoma
Daniel L. Faden et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2019)
TPExtreme randomized trial: TPEx versus Extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).
Joel Guigay et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Circulating exosomes measure responses to therapy in head and neck cancer patients treated with cetuximab, ipilimumab, and IMRT
Marie-Nicole Theodoraki et al.
ONCOIMMUNOLOGY (2019)
Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Miren Taberna et al.
FRONTIERS IN ONCOLOGY (2019)
Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer
Andrew Woolston et al.
CANCER CELL (2019)
Microenvironment plasticity confers cetuximab resistance
Peter Sidaway
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Management of skin toxicities during panitumumab treatment in metastatic colorectal cancer
Olivier Bouche et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2019)
Constitutive or Induced HIF-2 Addiction is Involved in Resistance to Anti-EGFR Treatment and Radiation Therapy in HNSCC
Pierre Coliat et al.
CANCERS (2019)
Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial
Hisham Mehanna et al.
LANCET (2019)
Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial
Maura L. Gillison et al.
LANCET (2019)
Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma
Madelyn Espinosa-Cotton et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Efficacy and Safety of Cetuximab plus Radiotherapy in Cisplatin-Unfit Elderly Patients with Advanced Squamous Cell Head and Neck Carcinoma: A Retrospective Study
Raffaele Addeo et al.
CHEMOTHERAPY (2019)
miR-204 inhibits angiogenesis and promotes sensitivity to cetuximab in head and neck squamous cell carcinoma cells by blocking JAK2-STAT3 signaling
Qingwei Wu et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
SMAD4 and NF1 mutations as potential biomarkers for poor prognosis to cetuximab-based therapy in Chinese metastatic colorectal cancer patients
Zhu Mei et al.
BMC CANCER (2018)
The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis
Wei-fa Yang et al.
ORAL ONCOLOGY (2018)
Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells
Pascale Andre et al.
CELL (2018)
Predictive Value of Cetuximab-Induced Skin Toxicity in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NECK
Shinya Uozumi et al.
FRONTIERS IN ONCOLOGY (2018)
High incidence of cetuximab-related infusion reactions in head and neck patients
Virginia Palomar Coloma et al.
ESMO OPEN (2018)
Anti PD-L1 DUrvalumab combined with Cetuximab and RadiOtherapy in locally advanced squamous cell carcinoma of the head and neck: A phase I/II study (DUCRO)
Pierluigi Bonomo et al.
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY (2018)
Tumor Mutational Burden and Response Rate to PD-1 Inhibition
Mark Yarchoan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Multicenter Phase II Study of Panitumumab in Platinum Pretreated, Advanced Head and Neck Squamous Cell Cancer
Marco Siano et al.
ONCOLOGIST (2017)
A comparison of weekly paclitaxel and cetuximab with the EXTREME regimen in the treatment of recurrent/metastatic squamous cell head and neck carcinoma
Kenji Nakano et al.
ORAL ONCOLOGY (2017)
IL6 is associated with response to dasatinib and cetuximab: Phase II clinical trial with mechanistic correlatives in cetuximab-resistant head and neck cancer
L. P. Stabile et al.
ORAL ONCOLOGY (2017)
MiR-223-3p inhibits angiogenesis and promotes resistance to cetuximab in head and neck squamous cell carcinoma
Alexandre Bozec et al.
ONCOTARGET (2017)
Integrative miRNA-Gene Expression Analysis Enables Refinement of Associated Biology and Prediction of Response to Cetuximab in Head and Neck Squamous Cell Cancer
Loris De Cecco et al.
GENES (2017)
A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
P. Bossi et al.
ANNALS OF ONCOLOGY (2017)
Human papillomavirus-related oropharyngeal cancer
M. Taberna et al.
ANNALS OF ONCOLOGY (2017)
SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells
Hiroyuki Ozawa et al.
CLINICAL CANCER RESEARCH (2017)
Differential pattern of HIF-1α expression in HNSCC cancer stem cells after carbon ion or photon irradiation: one molecular explanation of the oxygen effect
Anne -Sophie Wozny et al.
BRITISH JOURNAL OF CANCER (2017)
Functional Genomics Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab
Paolo Bossi et al.
CLINICAL CANCER RESEARCH (2016)
Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients
Sumita Trivedi et al.
CLINICAL CANCER RESEARCH (2016)
Correlation Between the Severity of Cetuximab-Induced Skin Rash and Clinical Outcome for Head and Neck Cancer Patients: The RTOG Experience
Voichita Bar-Ad et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2016)
Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015
Carmen J. Allegra et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death
Chiara Pozzi et al.
NATURE MEDICINE (2016)
Clinical recommendations for defining platinum unsuitable head and neck cancer patient populations on chemoradiotherapy: A literature review
Myung-Ju Ahn et al.
ORAL ONCOLOGY (2016)
Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma
Friederike Braig et al.
ONCOTARGET (2016)
Prognostic and predictive value of EGFR in head and neck squamous cell carcinoma
Paolo Bossi et al.
ONCOTARGET (2016)
Incidence and Risk Factors of Hypomagnesemia in Head and Neck Cancer Patients Treated with Cetuximab
Tomohiro Enokida et al.
FRONTIERS IN ONCOLOGY (2016)
Decreased SMAD4 expression is associated with induction of epithelial-to-mesenchymal transition and cetuximab resistance in head and neck squamous cell carcinoma
Haixia Cheng et al.
CANCER BIOLOGY & THERAPY (2015)
Correlation of cetuximab-induced skin rash and outcomes of solid tumor patients treated with cetwdmab: A systematic review and meta-analysis
Omar Abdel-Rahman et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2015)
Integrative and Comparative Genomic Analysis of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas
Tanguy Y. Seiwert et al.
CLINICAL CANCER RESEARCH (2015)
Phase II Study of Cetuximab in Combination with Cisplatin and Radiation in Unresectable, Locally Advanced Head and Neck Squamous Cell Carcinoma: Eastern Cooperative Oncology Group Trial E3303
Ann Marie Egloff et al.
CLINICAL CANCER RESEARCH (2014)
RAS/PI3K Crosstalk and Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma
T. Rampias et al.
CLINICAL CANCER RESEARCH (2014)
PD-L1 is a novel direct target of HIF-1α., and its blockade under hypoxia enhanced MDSC-mediated T cell activation
Muhammad Zaeem Noman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
mTOR Co-Targeting in Cetuximab Resistance in Head and Neck Cancers Harboring PIK3CA and RAS Mutations
Zhiyong Wang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Ocular side effects of biological agents in oncology: what should the clinician be aware of?
Tobias Hager et al.
ONCOTARGETS AND THERAPY (2014)
Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing
Sofia R. Gameiro et al.
ONCOTARGET (2014)
Differentiation of irradiation and cetuximab induced skin reactions in patients with locally advanced head and neck cancer undergoing radioimmunotherapy: the HICARE protocol (Head and neck cancer: ImmunoChemo and Radiotherapy with Erbitux) - a multicenter phase IV trial
G. Habl et al.
BMC CANCER (2013)
Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: Results from a randomized trial of the GERMAN AIO CRC Study Group
Sebastian Stintzing et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Cetuximab-mediated Tumor Regression Depends on Innate and Adaptive Immune Responses
Xuanming Yang et al.
MOLECULAR THERAPY (2013)
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Michael S. Lawrence et al.
NATURE (2013)
Anti-Epidermal Growth Factor Receptor Therapy in Head and Neck Squamous Cell Carcinoma: Focus on Potential Molecular Mechanisms of Drug Resistance
Carolien Boeckx et al.
ONCOLOGIST (2013)
Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review
Durga S. Borkar et al.
SUPPORTIVE CARE IN CANCER (2013)
Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
Vivian W. Y. Lui et al.
CANCER DISCOVERY (2013)
Targeting Stat3 Abrogates EGFR Inhibitor Resistance in Cancer
Malabika Sen et al.
CLINICAL CANCER RESEARCH (2012)
Cetuximab-induced pneumonitis in head and neck cancer patient
F. Y. F. L. De Vos et al.
ORAL ONCOLOGY (2012)
Epidermal Growth Factor Receptor Inhibition Augments the Expression of MHC Class I and II Genes
Brian P. Pollack et al.
CLINICAL CANCER RESEARCH (2011)
Serum biomarkers as potential predictors of antitumor activity of cetuximab-containing therapy for locally advanced head and neck cancer
Athanassios Argiris et al.
ORAL ONCOLOGY (2011)
Detection of Tumor Epidermal Growth Factor Receptor Pathway Dependence by Serum Mass Spectrometry in Cancer Patients
Christine H. Chung et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2010)
Association of Epidermal Growth Factor Receptor Polymorphism, Skin Toxicity, and Outcome in Patients with Squamous Cell Carcinoma of the Head and Neck Receiving Cetuximab-Docetaxel Treatment
Konrad Klinghammer et al.
CLINICAL CANCER RESEARCH (2010)
New Strategies in Head and Neck Cancer: Understanding Resistance to Epidermal Growth Factor Receptor Inhibitors
Lucy F. Chen et al.
CLINICAL CANCER RESEARCH (2010)
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival
James A. Bonner et al.
LANCET ONCOLOGY (2010)
Lack of Cetuximab induced skin toxicity in a previously irradiated field: case report and review of the literature
Madhava R. Kanakamedala et al.
RADIATION ONCOLOGY (2010)
Dasatinib blocks cetuximab- and radiation-induced nuclear translocation of the epidermal growth factor receptor in head and neck squamous cell carcinoma
Chunrong Li et al.
RADIOTHERAPY AND ONCOLOGY (2010)
Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells
Andres Lopez-Albaitero et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Skin toxicities associated with epidermal growth factor receptor inhibitors
Tianhong Li et al.
TARGETED ONCOLOGY (2009)
Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer:: a phase Ib/II study of the AIO GI Group
D. Arnold et al.
ANNALS OF ONCOLOGY (2008)
Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer
R. Rosell et al.
ANNALS OF ONCOLOGY (2008)
Interleukin-6 predicts recurrence and survival among head and neck cancer patients
Sonia A. Duffy et al.
CANCER (2008)
Erlotinib for advanced non-small-cell lung cancer in the elderly: An analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21
Paul Wheatley-Price et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial
Carole Fakhry et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Requirement of hypoxia-inducible factor-1α down-regulation in mediating the antitumor activity of the anti-epidermal growth factor receptor monoclonal antibody cetuximab
Xinqun Li et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Drug therapy: EGFR antagonists in cancer treatment
Fortunato Ciardiello et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Platinum-based chemotherapy plus cetuximab in head and neck cancer
Jan B. Vermorken et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Cellular responses to EGFR inhibitors and their relevance to cancer therapy
Pinaki R. Dutta et al.
CANCER LETTERS (2007)
FCGR2A and FCGR3A Polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab
Wu Zhang et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Severe cutaneous reaction during radiation therapy with concurrent cetuximab
Wilfried Budach et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Pharmacogenomic analysis of a randomized phase II trial (BOND 2) of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer
W. Zhang et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Diffuse punctate keratitis in a patient treated with cetuximab as monotherapy
M. V. Karamouzis et al.
ANNALS OF ONCOLOGY (2007)
Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer
Niklas Reimers et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Cutaneous side effects of epidermal growth factor receptor inhibitors: Clinical presentation, pathogenesis, and management
Jenny C. Hu et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2007)
Dermatologic side effects associated with the epidermal growth factor receptor inhibitors
Anna Liza C. Agero et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2006)
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
JA Bonner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma
J Loeffler-Ragy et al.
EUROPEAN JOURNAL OF CANCER (2006)
Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas
Christine H. Chung et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Plasma MIP-1β levels and skin toxicity in Japanese non-small cell lung cancer patients treated with the EGFR-targeted tyrosine kinase inhibitor, gefitinib
H Kimura et al.
LUNG CANCER (2005)
Pharmacokinetic profile of cetuximab (Erbitux™) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma
C Delbaldo et al.
EUROPEAN JOURNAL OF CANCER (2005)
Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors
S Segaert et al.
ANNALS OF ONCOLOGY (2005)
Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy
KK Ang et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2004)
The prognostic value of epidermal growth factor receptor is related to tumor differentiation and the overall treatment time of radiotherapy in squamous cell carcinomas of the head and neck
JG Eriksen et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2004)
An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors
ML Amador et al.
CANCER RESEARCH (2004)
Habitual risk factors for head and neck cancer
D Goldenberg et al.
OTOLARYNGOLOGY-HEAD AND NECK SURGERY (2004)
Therapeutic synergy of oral taxane BMS-275183 and cetuximab versus human tumor xenografts
WC Rose et al.
CLINICAL CANCER RESEARCH (2004)
ErbB-targeted therapeutic approaches in human cancer
CL Arteaga
EXPERIMENTAL CELL RESEARCH (2003)
Epidermal growth factor receptor-dependent control of keratinocyte survival and Bcl-xL expression through a MEK-dependent pathway
M Jost et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225
KJ Busam et al.
BRITISH JOURNAL OF DERMATOLOGY (2001)
分享论文
